Abstract | Objective: Methods: A comparison study of betahistine or placebo therapy was conducted for 4 weeks in 94 patients with chronic schizophrenia, who were randomly divided into two groups. Clinical information and lipid metabolic parameters were collected. Positive and Negative Syndrome Scale (PANSS) was used to assess psychiatric symptoms. Treatment Emergent Symptom Scale (TESS) was used to evaluate treatment-related adverse reactions. The differences in lipid metabolic parameters before and after treatment between the two groups were compared. Results: Repeated measures analysis of variance (ANOVA) revealed that after 4 weeks of betahistine/placebo treatment, the interaction effect of time and group was statistically significant on low-density lipoprotein cholesterol (F = 6.453, p = 0.013) and waist-to-hip ratio (F = 4.473, p = 0.037), but did not reveal any significant interaction effect of time and group on weight, body mass index or other lipid metabolic parameters, as well as the time main effect and group main effect (all p > 0.05). Betahistine had no significant impact on PANSS, and no side effects related to betahistine were detected. Conclusion:
|
Authors | Luyuan Bai, Weiye Liang, Yongqian Wang, Ning Fan, Qi Zhang, Yun Bian, Fude Yang |
Journal | Neuropsychiatric disease and treatment
(Neuropsychiatr Dis Treat)
Vol. 19
Pg. 453-460
( 2023)
ISSN: 1176-6328 [Print] New Zealand |
PMID | 36874957
(Publication Type: Case Reports, Clinical Trial)
|
Copyright | © 2023 Bai et al. |